These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21070984)

  • 1. Thymic carcinoma: is it a separate entity? From molecular to clinical evidence.
    Marx A; Rieker R; Toker A; Länger F; Ströbel P
    Thorac Surg Clin; 2011 Feb; 21(1):25-31. v-vi. PubMed ID: 21070984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of gene mutations in KIT-positive thymic epithelial tumors.
    Tsuchida M; Umezu H; Hashimoto T; Shinohara H; Koike T; Hosaka Y; Eimoto T; Hayashi JI
    Lung Cancer; 2008 Dec; 62(3):321-5. PubMed ID: 18486988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational status of EGFR and KIT in thymoma and thymic carcinoma.
    Yoh K; Nishiwaki Y; Ishii G; Goto K; Kubota K; Ohmatsu H; Niho S; Nagai K; Saijo N
    Lung Cancer; 2008 Dec; 62(3):316-20. PubMed ID: 18448188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors.
    Nakagawa K; Matsuno Y; Kunitoh H; Maeshima A; Asamura H; Tsuchiya R
    Chest; 2005 Jul; 128(1):140-4. PubMed ID: 16002927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas.
    Pan CC; Chen PC; Chiang H
    J Pathol; 2004 Mar; 202(3):375-81. PubMed ID: 14991904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathological aspects of malignant and benign thymic disorders.
    Müller-Hermelink HK; Marx A
    Ann Med; 1999 Oct; 31 Suppl 2():5-14. PubMed ID: 10574149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic utility of thymic epithelial markers CD205 (DEC205) and Foxn1 in thymic epithelial neoplasms.
    Nonaka D; Henley JD; Chiriboga L; Yee H
    Am J Surg Pathol; 2007 Jul; 31(7):1038-44. PubMed ID: 17592270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas.
    Kaira K; Oriuchi N; Imai H; Shimizu K; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
    J Surg Oncol; 2009 Jun; 99(7):433-8. PubMed ID: 19347882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy-relevant mutations of receptor tyrosine kinases in malignant thymomas and thymic carcinomas: a therapeutic perspective].
    Ströbel P; Knop S; Einsele H; Müller-Hermelink HK; Marx A
    Verh Dtsch Ges Pathol; 2007; 91():177-86. PubMed ID: 18314613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymomas and thymic carcinomas.
    Walker AN; Mills SE; Fechner RE
    Semin Diagn Pathol; 1990 Nov; 7(4):250-65. PubMed ID: 2284513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Surgery for thymomas and thymic carcinomas; treatment results in terms of WHO histologic typing, Masaoka staging system, and p53 expression].
    Yamazaki K; Kitada M; Sasaki K; Koshiko S; Hirasawa M; Ozawa K; Kajiura Y; Sasajima T; Miyokawa N
    Kyobu Geka; 2002 Oct; 55(11):949-52. PubMed ID: 12391691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical staining for bcl-2 and mcl-1 in intrathyroidal epithelial thymoma (ITET)/carcinoma showing thymus-like differentiation (CASTLE) and cervical thymic carcinoma.
    Dorfman DM; Shahsafaei A; Miyauchi A
    Mod Pathol; 1998 Oct; 11(10):989-94. PubMed ID: 9796728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas.
    Inoue M; Starostik P; Zettl A; Ströbel P; Schwarz S; Scaravilli F; Henry K; Willcox N; Müller-Hermelink HK; Marx A
    Cancer Res; 2003 Jul; 63(13):3708-15. PubMed ID: 12839963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas.
    Meister M; Schirmacher P; Dienemann H; Mechtersheimer G; Schnabel PA; Kern MA; Herpel E; Xu EC; Muley T; Thomas M; Rieker RJ
    Cancer Lett; 2007 Apr; 248(2):186-91. PubMed ID: 16919868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corpuscular thymoma: entity or variant of organotypical thymomas WHO B2/B3?
    Laeng RH; Eimoto T; Kuo TT; Zettl A; Marx A; Moschopulos M; Tateyama H; Shimokawa K
    Pathol Res Pract; 2006; 202(10):697-704. PubMed ID: 16887284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary carcinomas of the thymus gland.
    Ritter JH; Wick MR
    Semin Diagn Pathol; 1999 Feb; 16(1):18-31. PubMed ID: 10355651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferative activity and apoptosis in thymic epithelial neoplasms.
    Hiroshima K; Iyoda A; Toyozaki T; Supriatna Y; Shibuya K; Shimamura F; Haga Y; Yoshida S; Fujisawa T; Ohwada H
    Mod Pathol; 2002 Dec; 15(12):1326-32. PubMed ID: 12481014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymoma and thymic carcinoma: molecular pathology and targeted therapy.
    Ströbel P; Hohenberger P; Marx A
    J Thorac Oncol; 2010 Oct; 5(10 Suppl 4):S286-90. PubMed ID: 20859121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic treatment of advanced thymic malignancies.
    Kelly RJ
    Am Soc Clin Oncol Educ Book; 2014; ():e367-73. PubMed ID: 24857125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of neurotrophin receptors in surgically resected thymic epithelial tumors.
    Kim DJ; Yang WI; Kim SH; Park IK; Chung KY
    Eur J Cardiothorac Surg; 2005 Oct; 28(4):611-6. PubMed ID: 16125946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.